Rolling Out of Tenofovir Gel in Family Planning Clinics: The CAPRISA 008 Implementation Trial
Abstract
Product effectiveness in “real-world” settings in healthcare services may differ markedly from product efficacy observed in clinical trials. Limited data exists, beyond clinical trial settings, to guide the introduction of pre-exposure prophylaxis (PrEP) in healthcare services. Since a large number of young women utilise existing family planning (FP) services at primary healthcare clinics, these facilities present one of the best opportunities for introducing PrEP as a new HIV prevention technology for women as part of their well-established sexual and reproductive health services. CAPRISA 008 was a two-arm, open-label, randomised controlled, non-inferiority implementation trial, which provided participants from CAPRISA 004 with post-trial access to tenofovir gel while generating evidence that could be used for future implementation of topical PrEP (tenofovir gel) in women. Women were randomly assigned to receive tenofovir gel at clinical trial clinics or at FP clinics utilising Quality Improvement (QI) methodology to promote reliable service delivery. Higher adherence in FP clinics met the pre-defined non-inferiority criteria, demonstrating that integration of topical PrEP into FP services for African women is feasible, acceptable and achieves adherence equivalent to a clinical trial setting, providing evidence for PrEP scale-up using this strategy for this challenging high-priority population.
Keywords
Pre-exposure prophylaxis HIV prevention Adherence Integration into family planning services Tenofovir gel Implementation science Open-label clinical trial AdherenceReferences
- 1.Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science. 2010; 329: 1168–74.Google Scholar
- 2.Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women. N Eng J Med. 2015; 372(6): 509–18.Google Scholar
- 3.Rees H D-MS, Baron D, Lombard C, Gray G, Myer L, Panchia R, Schwartz J, Doncel G. FACTS 001 Phase III Trial of Pericoital Tenofovir 1 % Gel for HIV Prevention in Women [Abstract 26LB]. Conference on Retroviruses and Opportunistic Infections (CROI); 2015 23-26 February 2015; Seattle, Washington; 2015.Google Scholar
- 4.Mansoor LE, Abdool Karim Q, Mngadi KT, Dlamini S, Montague C, Nkomonde N, et al. Assessing the implementation effectiveness and safety of 1 % tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial. Trials. 2014; 15: 496.Google Scholar
- 5.Langley GJ. The improvement guide: a practical approach to enhancing organizational performance. 2nd ed. San Francisco: Jossey-Bass; 2009.Google Scholar
- 6.Berwick DM. Disseminating innovations in health care. JAMA. 2003; 289(15): 1969–75.Google Scholar
- 7.Barker PM, McCannon CJ, Mehta N, Green C, Youngleson MS, Yarrow J, et al. Strategies for the scale-up of antiretroviral therapy in South Africa through health system optimization. J Infect Dis. 2007; 196 (Suppl 3): S457–63.Google Scholar